171 related articles for article (PubMed ID: 37990076)
1. Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.
Kleef R; Dank M; Herold M; Agoston EI; Lohinszky J; Martinek E; Herold Z; Szasz AM
Sci Rep; 2023 Nov; 13(1):20360. PubMed ID: 37990076
[TBL] [Abstract][Full Text] [Related]
2. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer.
Lu Z; Zou J; Hu Y; Li S; Zhou T; Gong J; Li J; Zhang X; Zhou J; Lu M; Wang X; Peng Z; Qi C; Li Y; Li J; Li Y; Zou J; Du X; Zhang H; Shen L
JAMA Netw Open; 2019 Jul; 2(7):e197621. PubMed ID: 31339548
[TBL] [Abstract][Full Text] [Related]
3. Role of ion channels in gastrointestinal cancer.
Anderson KJ; Cormier RT; Scott PM
World J Gastroenterol; 2019 Oct; 25(38):5732-5772. PubMed ID: 31636470
[TBL] [Abstract][Full Text] [Related]
4. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.
Kleef R; Nagy R; Baierl A; Bacher V; Bojar H; McKee DL; Moss R; Thoennissen NH; Szász M; Bakacs T
Cancer Immunol Immunother; 2021 May; 70(5):1393-1403. PubMed ID: 33151369
[TBL] [Abstract][Full Text] [Related]
5. Serum CA724 has no diagnostic value for gastrointestinal tumors.
Cao H; Zhu L; Li L; Wang W; Niu X
Clin Exp Med; 2023 Oct; 23(6):2433-2442. PubMed ID: 36920593
[TBL] [Abstract][Full Text] [Related]
6. Local and Systemic IL-7 Concentration in Gastrointestinal-Tract Cancers.
Bednarz-Misa I; Diakowska D; Krzystek-Korpacka M
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31185636
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Poorly Differentiated Histology on Immunotherapy in Advanced Gastrointestinal Cancers.
Draper A; Jung EH; Cao Y; Atallah RP; Switchenko J; Kane S; Guadagno J; Jones AT; Brutcher E; Alese OB
Oncology; 2023; 101(4):213-223. PubMed ID: 36626879
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus and the risk of gastrointestinal cancer in women compared with men: a meta-analysis of cohort studies.
Fang HJ; Shan SB; Zhou YH; Zhong LY
BMC Cancer; 2018 Apr; 18(1):422. PubMed ID: 29661174
[TBL] [Abstract][Full Text] [Related]
9. The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis.
Liu XR; Wang LL; Zhang B; Liu XY; Li ZW; Kang B; Yuan C; Wei ZQ; Peng D
World J Surg Oncol; 2023 Mar; 21(1):81. PubMed ID: 36879283
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
11. Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.
Deutsch GB; Flaherty DC; Kirchoff DD; Bailey M; Vitug S; Foshag LJ; Faries MB; Bilchik AJ
JAMA Surg; 2017 Jul; 152(7):672-678. PubMed ID: 28384791
[TBL] [Abstract][Full Text] [Related]
12. Rising Incidence of Colorectal Cancer in Young Adults Corresponds With Increasing Surgical Resections in Obese Patients.
Hussan H; Patel A; Le Roux M; Cruz-Monserrate Z; Porter K; Clinton SK; Carethers JM; Courneya KS
Clin Transl Gastroenterol; 2020 Apr; 11(4):e00160. PubMed ID: 32352680
[TBL] [Abstract][Full Text] [Related]
13. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers.
Collienne M; Loghmani H; Heineman TC; Arnold D
Future Oncol; 2022 Aug; 18(26):2871-2878. PubMed ID: 35796248
[TBL] [Abstract][Full Text] [Related]
14. A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study.
Abdel-Rahman O
Int J Colorectal Dis; 2020 May; 35(5):911-920. PubMed ID: 32185469
[TBL] [Abstract][Full Text] [Related]
15. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
17. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
19. Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential.
Fares Amer N; Luzzatto Knaan T
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887399
[TBL] [Abstract][Full Text] [Related]
20. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
